Long-term effects of early Parkinson's treatments similar
A study published online today in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment. "Clinicians and patients often struggle with what is the right initial approach to treating Parkinson's disease," said University of Rochester Medical Center neurologist Kevin Biglan, M.D., M.P.H., the lead author of the paper and a member of the Parkinson's Study Group, an international network of researchers that oversaw the clinical trial. "This study tells us that, over the long haul, patients on the different drugs end up at roughly the same place in terms of their level of disability and quality of life."
Parkinson's disease is a progressive neurological disorder that erodes a person's control over their movements and speech. Over time, Parkinson's patients may experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremors in their hands, arms, legs, jaw or face.
The study compared two drugs – levodopa and pramipexole – that are generally employed as the first line of treatment for Parkinson's disease. The two drugs use different mechanisms to counteract the decline in the production of dopamine in the brain that is a result of a progressive loss of cells that secrete the neurochemical. Levodopa is an amino acid that the body metabolizes into dopamine. Pramipexole is a dopamine agonist that binds with dopamine receptors on cells in the brain and mimics the chemical's molecular function.
While levodopa is considered to be better at addressing the motor control symptoms of the disease such as mobility issues and tremors, it is also associated with side effects such as dyskinesia (involuntary movements) and the effectiveness of the drug can diminish, or wear off, over time. Pramipexole is less effective with respect to motor control symptoms and more often causes sleepiness, but is less commonly associated with dyskinesias and wearing off. Pramipexole is often prescribed because clinicians believe it essentially extends the window in which the patient can benefit from levodopa by delaying the initial use of the drug – and its eventually wearing off. Most Parkinson's patients end up taking levodopa at some point regardless of their initial treatment because it is more effective at improving the symptoms of the disease.
The initial study followed 301 Parkinson's patients in 22 sites in the U.S. and Canada over a 2 year period. A sub-set (222) of the group was followed for an additional 4 years. Half the patients were randomly assigned to be initially treated with levodopa and the other half with pramipexole. After 6 years of follow-up, essentially all of the participants (90%) were taking levodopa. The researchers evaluated study participants using tools that measure disability (ability to perform daily activities), side effects, disease severity, and the patient's sleepiness.
The study confirmed that patients who are initially treated with levodopa are more likely to develop motor complications such as dyskinesias and wearing off even 6 years after treatment. However, it also shows that these complications did not have a significant impact on the quality of life or disability of the patients.
"Clinicians and patients still need to establish their treatment priorities to understand unique circumstances that argue in favor of one drug vs. the other," said Biglan. "However, this study should assuage any concerns that the treatment decisions that are made early in the disease will have long-term implications, which does not appear to be the case."
- New animal study shows promise for development of Parkinson's disease drugThu, 9 Jun 2011, 12:10:07 EDT
- Are older antidepressants better for depression in Parkinson's disease?Wed, 17 Dec 2008, 16:36:26 EST
- Higher education level, greater disability associated with treatment timing in Parkinson's diseaseMon, 13 Jul 2009, 16:51:30 EDT
- Henry Ford neurologist outlines drug treatment for Parkinson's disease in NEJMThu, 4 Dec 2008, 5:58:26 EST
- Parkinson's disease treatments associated with compulsive behaviorsMon, 10 May 2010, 16:44:13 EDT
Articles on the same topic
- Parkinson's disease treatment strategies appear to have similar long-term effects on disabilityMon, 9 Mar 2009, 18:30:21 EDT
- Parkinson's disease treatment strategies appear to have similar long-term effects on disabilityfrom PhysorgMon, 9 Mar 2009, 19:07:12 EDT
- Parkinson disease treatment strategies appear to have similar long-term effects on disabilityfrom Science CentricMon, 9 Mar 2009, 18:28:19 EDT
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Outlook is grim for mammals and birds as human population grows
- Mars had oxygen-rich atmosphere 4,000 million years ago
- The contribution of particulate matter to forest decline
- Scientists find new source of versatility so 'floppy' proteins can get things done
- An environmentally friendly battery made from wood
- Even with defects, graphene is strongest material in the world
- Detection of the cosmic gamma ray horizon: Measures all the light in the universe since the Big Bang
- Genetic engineering alters mosquitoes' sense of smell
- Allosaurus fed more like a falcon than a crocodile, new study finds
- 'Popcorn' particle pathways promise better lithium-ion batteries